Takeda further enables hemophilia a personalized care with launch of mypkfit® software for adynovate® [antihemophilic factor (recombinant), pegylated]

Cambridge, mass. and osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced the u.s. availability of mypkfit® for adynovate® [antihemophilic factor (recombinant), pegylated], a web-based software and mobile application that is the first and only pharmacokinetic (pk)-dosing software approved by the u.s. food and drug administration (fda) for hemophilia a patients 12 and older and weighing at least 29 kg treated with adynovate.1 the myp
TAK Ratings Summary
TAK Quant Ranking